Genmab is an undervalued antibody-platform leader using Darzalex royalty cash flows to fund a higher-risk, higher-upside transition into a fully integrated oncology powerhouse.
Overview
Genmab is a Danish antibody-therapy biotech transitioning from a high-margin royalty model into a more integrated commercial oncology company. Its royalty base, especially Darzalex, provides strong non-dilutive funding for R&D and acquisitions, while Epkinly, Tivdak, Rina-S, and petosemtamab expand its owned or co-owned commercial opportunity. Proprietary antibody platforms offer differentiation in bispecifics, ADCs, and subcutaneous administration. The investment case depends on successfully converting royalty cash flows into durable wholly owned growth before Darzalex royalties fade in the early 2030s.